This 1.5 day workshop will focus on the European experience with biosimilar medicinal products. The workshop will give an overview of the current regulatory as well as market-access situation for these products. Moreover, the lessons learned and the challenges faced by two classes of products, among the first classes of biosimilars approved in the EU, Erythropoietin (EPO) and Granulocyte-Colony Stimulation Factor (G-CSF) will be addressed and put into perspective for the most recently approved biosimilars monoclonal antibodies.
Explore
